ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL

BACKGROUND: The CeTeG/NOA-09 trial recently showed a survival benefit for combination chemotherapy with CCNU/TMZ in glioblastoma patients with a methylated MGMT promoter as determined by quantitative Methylation-Specific PCR (qMSP). Identifying patient subgroups with a pronounced benefit from this n...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Tzaridis, Theophilos, Schäfer, Niklas, Weller, Johannes, Steinbach, Joachim, Seidel, Sabine, Schlegel, Uwe, Sabel, Michael, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Tonn, Joerg-Christian, Grauer, Oliver, Schaub, Christina, Coch, Christoph, Glas, Martin, Pietsch, Torsten, Fimmers, Rolf, Reifenberger, Guido, Felsberg, Jörg, Herrlinger, Ulrich
Format: Artigo
Language:Inglês
Published: Oxford University Press 2019
Subjects:
Adult Clinical Trials - Non-Immunologic
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847379/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.095
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items